President Donald Trump was treated with an experimental antibody cocktail for Covid-19 and moved to a military hospital as a precautionary measure, White House officials said.
iBio’s FastPharming Platform Produces Decoy Therapeutic to Bind to SARS-CoV-2
ACE2 (angiotensin-converting enzyme-2), Business, Immunoadhesin Molecules, Licensing, Product Pipeline, R&D, Recombinant Proteins, SARS-CoV-2 spike protein, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), TherapeuticsiBio Inc. is developing a decoy molecule as a therapeutic against SARS-CoV-2.